As we look back over the past year and forward to the future, we are grateful to our valued customers and partners, and the trust they place in us is our greatest gift. 🎁
But without our employees, nothing would be possible. That’s why we thank everyone at ETAP-Lab, STROK@lliance and SYNCROSOME. We appreciate their dedication, passion and positive attitude on every day.
With our teams growing, we’re convinced that this new year will be a great one ! We look forward to reaching new milestones together in the coming year.
🎄We wish you a joyful and peaceful festive season, and a Happy New Year 2025 to all !
📌ETAP-Lab is delighted to present for the first time a poster at the American Heart Association’s annual International Stroke Conference 2025, in Los Angeles, CA from February 5 to 7, 2025.
As a leading international conference in cerebrovascular disease and brain health, the AHA’s International Stroke Conference was the ideal platform to highlight our preclinical stroke research expertise.
ETAP-Lab, preclinical efficacy CRO, will be presenting its poster on original preclinical results about in vivo trials on Stroke disease.
📅Meet our expert during the poster session
Annelise LETOURNEUR, Director of Operations at STROK@LLIANCE and Neuroscience Study Director, will present the poster “ Translational Relevance and Versatility of the Thromboembolic Stroke Model in Mice: Implications for Pharmacological and Safety Evaluations” (#4166454).
Session details to come later.
🧠Our specific stroke models, reproducing translational challenges.
Would you like to support the development of your neurological drugs with translational preclinical models?
Thanks to our robust expertise in preclinical neurology, we can advise with relevant and translatable range of stroke models from in vitro to in vivo. Our key innovation is to offer models in optimal translational situations that combine stroke with metabolic diseases, diabetes or aging.
We are delighted to announce the renewal of ETAP-Lab’s ISO 9001 certification. This achievement underlines our commitment to providing exemplary preclinical research services.
A commitment to quality and customer satisfaction
Our robust quality management system, backed by our ISO9001 certification, ensures to our customers:
compliance with rigorous quality standards: we follow established protocols and guidelines to ensure the accuracy and reliability of our services.
Continuous improvement: We constantly focus on improving our processes and services, driven by a commitment to excellence.
Customer-focused approach: Your satisfaction is essential to us. We work closely with you to understand your specific needs and provide tailor-made solutions.
When you choose ETAP-Lab, you benefit from our proven experience in providing high-quality preclinical research services. Our team of experienced scientists and technicians is dedicated to providing the highest level of expertise and support.
The certificate was granted by OFC from October 2, 2024 to October 1, 2027 for its Quality Management System for
“consulting, advising and expertise of studies in the field of in vitro and in vivo preclinical research”.
📌ETAP-Lab is happy to present a poster at the 16th World Stroke Congress (WSC 2024) in Abu Dhabi, UAE, from October 23-26, 2024 organized by the World Stroke Organization.
ETAP-Lab’s team is looking forward to attending this global event that explores “the forefront of stroke and cerebrovascular disease topics and present the most influential late breaking clinical trials”.
As a preclinical efficacy CRO, ETAP-Lab will unveil its poster on original preclinical results about in vivo assays on Stroke disease.
The results presented have been possible also thanks to STROKTURA* program.
📅Join our expert during the poster session
Annelise LETOURNEUR, Director of Operations at STROK@LLIANCE and Neuroscience Study Director, will present the poster
“Translational models of hemorrhagic transformation to evaluate the safety of new therapies in acute stroke: effects of age and hypertension in diabetic mice“.
Session details:
Session Name: 0460 – SHORT COMMUNICATIONS 02: BASIC SCIENCE AND TRANSLATIONAL RESEARCH & DATA SCIENCES AND ARTIFICIAL INTELLIGENCE (ID 1584)
Date : Wed, 23.10.2024
Session Time: 14:00 – 15:30
Room: Hall G
Lecture Time: 14:56 – 15:00
🧠Our specific stroke models, reproducing translational challenges.
Would you like to support the development of your neurological drugs with preclinical studies? Do you need to test the efficacy of your molecules in translational models that mimic different commorbidity parameters?
Thanks to our robust expertise in preclinical neurology, we can advise with relevant and translatable range of stroke models from in vitro to in vivo. Our key innovation is to offer models in optimal translational situations that combine stroke with metabolic diseases, diabetes or aging.
STROKTURA, Stroke for the Future, aims to find innovative solutions in brain imaging applied to preclinical models of stroke, with the purpose of testing future therapies for ischemic strokes in humans. This project, led by our team of experts in collaboration with BB@C, with scientific and technical support from PhIND, ESR3P, and CYCERON, is financially supported by FEDER and the Normandy Region.
Inauguration of the STROK@LLIANCE building in the presence of local officials in Caen
CAEN – ETAP-Lab, an independent French contract research organization (CRO), will inaugurate its new research laboratory, STROK@LLIANCE, on September 17, 2024, at 14:30. The event will take place on the Jules Horowitz campus in Caen, with the participation of its partners and representatives from the University of Caen-Normandy, Caen la Mer, and the Normandy Region.
A multi-voice ceremony
For this inauguration ceremony at STROK@LLIANCE, Nicolas Violle, CEO of ETAP-Lab, is pleased to bring together employees from ETAP-Lab’s three sites, as well as its partners – notably ESR3P, CYCERON, and BB@C. ETAP-Lab also has the privilege of welcoming local stakeholders, with speeches from the President of the University of Caen-Normandy, representatives of the urban community Caen la Mer, and the Normandy Region. Professor Denis Vivien (PU-PH), a renowned scientist and Director of the BB@C institute and the PhIND Laboratory, will also speak, along with Hugues Contamin, President of AFSSI (French Association of Service and Innovation Companies for Life Sciences), representing the French preclinical CRO sector to which ETAP-Lab belongs.
A sustainable local presence, promoting employment, research, and innovation
Established in Caen for 7 years under the brand name STROK@LLIANCE, and leveraging the research of its academic partner PhIND, ETAP-Lab has experienced significant growth – directly creating 13 jobs on site. To support its growth, it decided to increase its capacity by acquiring a building on the Jules Horowitz campus. After a year of renovation and expansion work, the teams moved into this new building, fully operational since July 2024. ETAP-Lab invested 2.4 million euros in this project, mostly funded by its own resources, with financial support from Caen la Mer through a zero-interest loan of 250,000 euros and a 50,000-euro grant from the Normandy Region.
Stroke, a global health challenge, supported by preclinical companies
Each year, 15 million people worldwide suffer a stroke, with one-third of patients dying within the following weeks and another third suffering permanent disability. In France, 130,000 people are affected by stroke each year. STROK@LLIANCE offers preclinical stroke models and is involved in the early stages of drug candidate development for the pharmaceutical industry. By providing cutting-edge preclinical research services, it rigorously and independently evaluates the efficacy and safety of its clients’ molecules – a prerequisite before any clinical trial in humans.
STROK@LLIANCE: Enhanced capabilities to meet the accelerating stroke research needs of the pharmaceutical industry
Currently, there is only one emergency treatment for strokes, and epidemiological studies predict a 70-80% increase in their incidence by 2050. In this context, the pharmaceutical industry is intensifying its research to develop new therapeutic solutions. The new 700 m² facilities of STROK@LLIANCE meet clients’ needs by tripling neurology research capacities while remaining at the heart of biomedical research and innovation at the CYCERON center. With its extensive experience in preclinical pharmacology and the integration of innovations from the PhIND laboratory, ETAP-Lab offers its unique expertise to its clients. Since 2017, its research has contributed to the development of numerous molecules, representing new hopes for stroke treatment.
About ETAP-Lab
ETAP-Lab is an independent contract research organization (CRO) established in 1991 in Vandoeuvre-Lès-Nancy (Grand-Est). It offers efficacy and safety evaluation services for drug candidates to pharmaceutical and biotechnology industries – an essential step before any clinical trial of innovative therapies in humans. With over 30 years of scientific expertise, it supports clients with preclinical studies in various therapeutic areas, including Dermatology, Neurology, and Cardiology, through the integration of SYNCROSOME in October 2023. With a team of 45 employees across three sites in France, ETAP-Lab supports over 300 clients worldwide. In 2023, its turnover reached 3.4 million euros (+74%), with 80% from exports. It strengthens its market position through external growth and strategic research projects.
For more information:
ESR3P: Experimental platform dedicated to stroke at the University of Caen-Normandy, affiliated with INSERM UMR-S 1237, PhIND, directed by Professor Denis VIVIEN.
STROK@LLIANCE: Born from the virtuous association between ETAP-Lab and ESR3P, offering the best of academic and CRO expertise in the field of stroke within a state-of-the-art scientific and technological complex.
👷♂️ A year ago, we announced the first stone of the new building for our Strok@lliance site in Caen.
📢 Today we’re delighted to announce that the building is up and running, with the laboratory section now ready for occupancy.
This is an important event for Strok@lliance, our site of excellence dedicated to stroke at the very best heart of a research center with the support of ESR3P, CYCERON and Institut BB@C.
👉 Follow with us the completion of the installation over the coming weeks…
